CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 128 enrolled
Drug / intervention
autologous cultured chondrocytes on porcine collagen membrane +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01251588
NCT01251588N/ACompleted

An Extension Protocol for Participants of Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle Including the Trochlea

Vericel Corporation·observational·Posted Dec 2, 2010·Updated May 12, 2021

In Brief

An observational study evaluating autologous cultured chondrocytes on porcine collagen membrane and Microfracture for Articular Cartilage Defects. Completed, enrolled 128 participants across 14 sites in 7 countries.

Detailed Summary

To examine the 5-year efficacy and safety of MACI implant, compared with arthroscopic microfracture, in participants who received study treatment in the SUMMIT study for treatment of symptomatic articular cartilage defects of the knee.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesCzechia, France, Netherlands, Norway, Poland, Sweden, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2, 2010
Enrollment StartDec 1, 2010
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 15.6 years ago

Interventions

autologous cultured chondrocytes on porcine collagen membranebiological

Implantation received in the previous MACI00206 study

Microfractureprocedure

Arthroscopic Microfracture treatment received in the previous MACI00206 study